THCT stock plunged to $0.0002 on 06 Mar 2026 during market hours, a -98.89% one-day swing from the prior close of $0.0180. That collapse left trading extremely thin with volume 1,000 shares and a market cap of $7,773.00 on the PNK exchange in the United States, USD. Investors should treat moves like this as liquidity-driven and news-sensitive. We examine drivers, financials, technicals, and Meyka AI model forecasts for THC Therapeutics, Inc. to highlight practical watch points and risk controls.

Intraday snapshot for THCT stock

THCT (THC Therapeutics, Inc., PNK) closed at $0.0002 with a one-day change of -98.89% and a day range of $0.0001 to $0.0002. Volume hit 1,000 versus average volume 7,485, showing weak liquidity. Shares outstanding are 38,866,149, giving a market capitalization of $7,773.00. The stock trades in USD on the PNK exchange in the United States and shows extreme price dispersion versus 50-day and 200-day averages of $0.00319 and $0.00092 respectively.

Why THCT stock is a top loser today

The company issued a March 3 shareholder update and filed a 10-K as it rebuilds operations in legal cannabis, but the market reacted with a sharp selloff. Management highlighted acquisitions and a plan to return to fully reporting status, yet the Expert Market classification and low float limit price discovery. See the corporate update for details Business Insider and basic financials on Reuters Reuters. Thin trading, low cash per share, and conversion risk of illiquid holdings often amplify down moves in micro-cap names.

Financials, valuation and immediate risks for THCT stock

Key metrics show material stress. EPS is -0.02 and reported PE is -0.01. Enterprise Value sits near $799,200.00, producing distorted multiples given the tiny market cap. Book value per share is -0.1009, and cash per share is near zero. The current ratio is 0.00030, and debt-to-assets is 60.93%, highlighting balance sheet strain. These figures point to high dilution and restructuring risk, making valuation comparisons with peers in Healthcare and Drug Manufacturers unreliable without clearer revenue disclosure.

Meyka grade and technical analysis for THCT stock

Meyka AI rates THCT with a score out of 100: 64.96, Grade B, Suggestion HOLD. This grade factors S&P 500 and sector comparison, industry positioning, financial growth, key metrics, forecasts, and analyst signals. Technical indicators show RSI 45.44 and ADX 22.65, indicating a weak trend. On-balance volume is deeply negative and volatility is high. Our grading is informational only and not investment advice. The company’s reported gauge of operations and filings were included in the grade calculation.

Price forecasts, targets and model projections for THCT stock

Meyka AI’s forecast model projects a range of outcomes: monthly $0.01, one-year $0.00093, three-year $0.00129, five-year $0.00166, and seven-year $0.00266. Versus the current price $0.0002, the one-year implied change is about +366.06%, and the monthly projection implies +4,900.00%. These model outputs reflect scenario-driven recovery paths and are sensitive to liquidity and successful integration of acquired assets. Forecasts are model-based projections and not guarantees.

Trading strategy and watch points for THCT stock

Given volatility and sparse volume, prioritize capital preservation. Watch for continued SEC filings, investor relations updates, and proof of revenue from acquired subsidiaries. Avoid margin and large position sizing. If you trade, use limit orders and set tight stop-loss rules. Monitor sector moves in cannabis wellness and specialty drug manufacturers, and track average volume and price discovery metrics on THCT on Meyka.

Final Thoughts

THCT stock’s drop to $0.0002 on 06 Mar 2026 reflects liquidity stress, reporting history, and market skepticism about recent acquisitions. Financials show negative EPS -0.02, tiny cash per share, and a market cap of $7,773.00, which together raise dilution and solvency concerns. Meyka AI’s model projects a one-year level of $0.00093 (implied +366.06% from current price) and a monthly scenario at $0.01 (implied +4,900.00%). These forecasts assume successful integration and clearer reporting. Our grade places THCT at 64.96 (B, HOLD) reflecting mixed fundamentals and potential upside if operations scale. Investors should treat the name as speculative, follow filings, and limit exposure to avoid outsized losses from thin-market moves. Forecasts are model-based projections and not guarantees, and we remind readers that this is informational analysis from Meyka AI, an AI-powered market analysis platform.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.